LANSING, MI - Ingham County Health Officer Linda Vail expressed concerns regarding the new COVID-19 vaccines from Johnson and Johnson during a media briefing on Tuesday afternoon.

“I’m a little disappointed that the efficacy is a little bit lower and I think that’s going to cause some problems in the sense that people are going to say ‘I don’t want that vaccine I want the other one’.” said Vail.

Data shows that the Janssen COVID-19 vaccine is 66% effective. The trial included 43,783 participants who were positive for COVID-19. 468 of them were symptomatic.

Unlike the Moderna and Pfizer vaccine, the Janssen COVID-19 vaccine Adenovirus, which is a group of viruses typically found in a common cold. The Janssen shot is similar to the technology of a flu shot- a small amount of the virus is infected into the body so the immune system can learn to fight it off.

The Janssen vaccine is administered in a single dose and starts working 28 days after it is administered. It is viable for up to two years if stored at -20°C (-4°F) or three months at 2-8°C (36°F–46°F).

If the U.S. Food and Drug Administration authorizes it for emergency use, Johnson and Johnson predicts that there could be less than 20 or 30 million vaccines available by April.

“Herd immunity is going to occur between the combination of vaccines if we get to that 80% range, even if we have some vaccines out there that are not as effective,” said Vail.